Holen Sie sich die Stockscreener-App
5.3916
2.53%
-0.1384
Savara Inc Aktie (SVRA) Neueste Nachrichten
When Can We Expect A Profit From Savara Inc. (NASDAQ:SVRA)? - Moomoo
Will Long-Term IMPALA-2 aPAP Data at ERS 2026 Change Savara's (SVRA) Narrative - simplywall.st
Savara stock holds steady as investors focus on lead lung therapy - AD HOC NEWS
Savara Grants Equity Awards to Eight New Employees - MyChesCo
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Savara (SVRA) Results at a Glance: Profit Per Share Falls Below Its Benchmark for This Review; Market Response: Shares Finish 0.72% Higher for the Current SessionProfit Margin Analysis - vinanet.vn
Does Phase 3 IMPALA-2 aPAP Data at ERS 2026 Change The Bull Case For Savara (SVRA)? - simplywall.st
Savara presents molgramostim data at ERS Congress in September By Investing.com - Investing.com Canada
Savara presents molgramostim data at ERS Congress in September - Investing.com
Why Savara (SVRA) Is Getting Attention Today - Sahm
Savara Announces New Employment Inducement GrantAugust 20, 2026 - BioSpace
Savara (SVRA) Quarterly Results: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Trading Response: Shares Move 3.91% Higher for the Current SessionEarnings Outlook Update - dars.gov.et
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $11 - Moomoo
Savara (SVRA) Advances 2.09% to $5.38 as Aerosol Therapy Momentum BuildsStock Analysis - Vinanet
SVRA Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage Pipeline InvestmentPeak Earnings Alert - vinanet.vn
Savara Inc. (SVRA) Gains 2.09% to $5.38, Holding Support at $5.11Triple Top - vinanet.vn
Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA - MarketBeat
Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for Savara - MarketBeat
Savara (NASDAQ:SVRA) Stock Price Down 5.4%What's Next? - MarketBeat
HC Wainwright Has Pessimistic View of Savara FY2029 Earnings - marketbeat.com
Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA) - The Globe and Mail
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf - simplywall.st
Savara Inc. (SVRA) Advances 1.17% as Rare Disease Focus Draws Continued Interest — Resistance at $5.91 in SightPrice Momentum Stocks - Vinanet
Savara Inc. (SVRA) Slips 2.79% as Shares Test Key Support at $5.29Revenue Weighted - Vinanet
Wells Fargo Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
SAVARA Q2 EPS USD -0.16 - Moomoo
Savara Q2 loss widens to $40M on surging commercial costs - scanx.trade
Savara Inc (SVRA) Advances MOLBREEVI Launch Amid High Price-to-S - GuruFocus
Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Savara Inc. Announces Q2 2026 Financial Results with Increased Net Losses - Kalkine Media
Savara Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Savara Q2 loss widens as operating expenses rise - TradingView
Savara Inc 2Q 2026: Net loss $(40.2M), EPS $(0.16) — 10-Q Summary - TradingView
BRIEF-Savara Q2 Net Income USD -40.228 Million - TradingView
Savara Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC - MarketBeat
Savara Inc (YB4P.SG) recent insider transactions - au.finance.yahoo.com
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem With 88.90% Potential Upside - DirectorsTalk Interviews
Savara investors brace for earnings ahead of crucial FDA review By Investing.com - Investing.com Nigeria
Savara (SVRA) to Announce Quarterly Earnings on Wednesday - MarketBeat
SVRA Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
Savara: High-Potential Binary Bet Cruising To PDUFA After A 3 Month Speed Bump (SVRA) - Seeking Alpha
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
SVRA Q1 2026 Earnings: Wider Loss Than Expected as Pre-Revenue Biotech Navigates Pipeline CostsEarnings Weakness Phase - vinanet.vn
Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA - MarketBeat
Savara Inc. (SVRA) Slips to $5.44 as Rare Disease Biotech Holds Support ZoneBreakout Stock Alerts - dars.gov.et
Levi & Korsinsky Urges Savara Inc. (SVRA) Shareholders to Act Before Lead Plaintiff Deadline November 7, 2025 - The National Law Review
Savara Inc. (SVRA) Gains 2% as Shares Test Key Resistance LevelsVolume Dry Up - dars.gov.et
Savara secures European, Australian patents for MOLBREEVI By Investing.com - Investing.com Nigeria
Savara Inc. $SVRA Shares Bought by Eversept Partners LP - marketbeat.com
SVRA|Savara Inc|Price:5.435|Chg%:-0.075 - TradingKey
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Savara Inc (SVRA) Institutional Confidence - TradingKey
Orbimed Advisors LLC Acquires Shares of 635,000 Savara Inc. $SVRA - MarketBeat
Savara Inc (SVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):